Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cells

Melanoma Research

Volumn 6, Issue 3, 1996, Pages 183-189

  Benathan, M ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

5 S cysteinyldopa; Cysteine; Glutathione; Melanogenesis; Melanoma cells; Tyrosine

Indexed keywords

BUTHIONINE SULFOXIMINE; CATECHOL OXIDASE; CYSTEINE; CYSTEINYLDOPA; GLUTATHIONE; MELPHALAN; MONOPHENOL MONOOXYGENASE;

ARTICLE; BIOSYNTHESIS; DRUG CYTOTOXICITY; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MELANOGENESIS; MELANOMA CELL; PRIORITY JOURNAL;

BUTHIONINE SULFOXIMINE; CATECHOLS; CELL LINE; CYSTEINE; CYSTEINYLDOPA; GLUTATHIONE; HUMANS; MELANOMA; MICROSCOPY, ELECTRON; MONOPHENOL MONOOXYGENASE; TUMOR CELLS, CULTURED;

EID: 0029956985     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199606000-00001     Document Type: Article

References (37)

1. Hansson J, Edgren M, Ehrsson H, Ringborg U, Nilsson B. Effect of D,L-buthione-S,R-sulphoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells. Cancer Res 1988; 48: 19-26.
2. Hansson J, Berhane K, Castro VM, et al. Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid. Cancer Res 1991; 51: 94-98.
3. Dulik DM, Fenselau C. Conversion of melphalan to 4-(glutathionyl) phenylalanine. A novel mechanism for conjugation by glutathione-S-transferases. Drug Metab Dis 1987; 15: 195-199.
4. Benathan M, Alvero-Jackson H, Mooy A-M, Scaletta C, Frenk E. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells. Melanoma Res 1992; 2: 305-314.
5. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Egushi H. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994; 73: 629-636.
6. Peterson LL, Woodward WR, Fletcher WS, et al. Plasma 5-S-cysteinyldopa differentiates patients with primary metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects. J Am Acad Dermatol 1988; 19: 509-515.
7. Agrup G, Falck B, Fyge K, et al. Excretion of 5-S-cysteinyldopa in the urine of healthy subjects. Acta Dermatol Venereol 1975; 55: 7-9.
8. Westerhof W, Pavel S, Kammeyer A, Beusenberg FD, Cormane R. Melanin related metabolites as markers of the skin pigmentary system. J Invest Dermatol 1987; 89: 78-81.
9. Stierner U, Rosdahl I, Augustsson A, Kågedal B. Urinary excretion of 5-S-cysteinyldopa in relation to skin type, UVB-induced erythema, and melanocyte proliferation in human skin. J Invest Dermatol 1988; 91: 506-510.
10. Benathan M, Scaletta C, Frenk E. Demonstration of tyrosinase-dependent and tyrosinase-independent 5-S-cysteinyldopa genesis in vitro. Melanoma Res 1994; 4 (Suppl 2): 14.
11. Prota G. Regulatory mechanisms in melanogenesis: beyond the tyrosinase concept. J Invest Dermatol 1993; 100: 156S-161S.
12. Ito S, Prota G. A facile one-step synthesis of cysteinyldopa using mushroom tyrosinase. Experientia 1977; 33: 1118-1119.
13. Ito S, Palumbo A, Prota G. Tyrosinase-catalyzed conjugation of dopa with glutathione. Experientia 1985; 41: 960-961.
14. d'Ischia M, Napolitano A, Prota G. Sulphydryl compounds in melanogenesis. Part 1. Reactions of cysteine and glutathione with 5,6-dihydroxyindoles. Tetrahedron 1987; 43: 5351-5356.
15. d'Ischia M, Napolitano A, Prota G. Sulphydryl compounds in melanogenesis. Part 2. Reactions of cysteine and glutatione with dopachrome. Tetrahedron 1987; 43: 5357-5362.
16. Carstam R, Hansson C, Lindbladh, Rorsman H, Rosengren E. Dopaquinone addition products in cultured human melanoma cells. Acta Dermatol Venereol 1987; 67: 100-105.
17. Aubert Ch, Rouge F, Reillaudou M, Metge P. Establishment and characterization of human ocular melanoma cell lines. Int J Cancer 1993; 54: 784-792.
18. Agrup G, Falck B, Kennedy B-M, et al. Formation of cysteinyldopa from glutathionedopa in melanoma. Acta Dermatol Venereol 1975; 55: 1-3.
19. Kågedal B, Gawelin A-L, Pettersson A. Synthesis of 5-S-L-cysteinyl-glycine-L-Dopa, a natural substrate for serum and melanocyte dipeptidase. Anal Biochem 1987; 165: 167-174.
20. Mojamdar M, Ichihashi M, Mishima Y. γ-Glutamyl transpep21. tidase, tyrosinase, and 5-S-cysteinyldopa production in melanoma cells. J Invest Dermatol 1983; 81: 119-121.
21. Chakraborty AK, Ishihashi M, Mishima Y. Effect of dopa-loading on glutathione metabolizing enzymes and tyrosinase in relation to 5-S-cysteinyl-DOPA genesis in culture B-16 melanoma cells. J Dermatol Sci 1991; 2: 329-335.
22. Rorsman H, Albertsson E, Edholm L-E, et al. Thiols in the melanocytes. Pigment Cell Res 1988; 1 (Suppl 1): 54-60.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RS. Protein measurements with the Folin phenol reagent. J Biol Chem 1951; 193; 265-275.
24. Stein AF, Dills RL, Klaassen CD. High-performance liquid chromatographic analysis of glutathione and its thiol and disulphide degradation products. J Chromatogr 1986; 381: 259-270.
25. Ito S, Kato T, Maruta K, Fujita K. Determination of DOPA, dopamine, and 5-S-cysteinyl-DOPA in plasma, urine, and tissue samples by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1984; 311: 154-159.
26. Karg E, Rosengren E, Rorsman H. Hydrogen peroxide as a mediator of dopac-induced effects on melanoma cells. J Invest Dermatol 1991; 96: 224-227.
27. Townsend DW, Olds DP, King RA. Dopa oxidase activity in human hair bulbs measured by high-performance liquid chromatography. J Invest Dermatol 1986; 86: 570-572.
28. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988; 263: 17205-17208.
29. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulphoximine (S-n-butyl homocysteine sulphoximine). J Biol Chem 1979; 254: 7558-7560.
30. Slominski A, Constantino R. Molecular mechanisms of tyrosinase regulation by L-dopa in hamster melanoma cells. Life Sci 1991; 48: 2075-2079.
31. Schadendorf D, Jurgovsky K, Kohlmus CM, Czarnetzki BM. Glutathione and related enzymes in tumour progression and metastases of human melanoma. J Invest Dermatol 1995; 105: 109-112.
32. Riley PA. Melanogenesis: a realistic target for antimelanoma therapy? Eur J Cancer 1991; 27: 1172-1177.
33. Naish-Byfield, Cooksey CJ, Latter AM, Johnson CI, Riley PA. In vitro assessment of the structure-activity relationship of tyrosinase-dependent cytotoxicity of a series of substituted phenols. Melanoma Res 1991; 1: 273-287.
34. Jimbow K, Iwashina T, Alena F, et al. Exploitation of pigment biosynthetic pathway as a selective chemotherapeutic approach for malignant melanoma. J Invest Dermatol 1993; 100: 231S-238S.
35. Kable EPW, Favier D, Parsons PG. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulphoximine. Cancer Res 1989; 49: 2327-2331.
36. Prezioso JA, Fitzgerald GB, Wick MM. Effects of tyrosinase activity on the toxicity of 3,4-hydroxybenzylamine and buthionine sulphoximine in human melanoma cells. Pigment Cell Res 1990; 3: 49-54.
37. Alena F, Dixon W, Thomas P, Jimbow K. Glutathione plays a key role in the depigmenting and melanocytotoxic action of N-acetyl-4-S-cysteaminylphenol in black and yellow hair follicles. J Invest Dermatol 1995; 104: 792-797.